{"nctId":"NCT02446743","briefTitle":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","startDateStruct":{"date":"2015-11-17","type":"ACTUAL"},"conditions":["Infections, Meningococcal"],"count":531,"armGroups":[{"label":"Group 3B","type":"EXPERIMENTAL","interventionNames":["Biological: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)"]},{"label":"Group B_0_1","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)"]}],"interventions":[{"name":"rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inclusion Criterion for follow-on subjects:\n* Individuals who participated to Study V72\\_41 or V72P10 and have completed vaccination with rMenB+OMV NZ according to a 2-dose schedule\n\nInclusion Criterion for naïve subjects:\n\n* Individuals of 15 through 21 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72\\_41.\n* 17 through 24 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72P10.\n\nInclusion Criteria for all subjects:\n\n* Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.\n* Individuals who can comply with study procedures including follow-up.\n* Males Or Females of non-childbearing potential Or Females of childbearing potential who are using an effective birth control method .\n\nExclusion Criteria for all subjects\n\nExclusion Criterion for follow-on subjects:\n\n• Received a third dose of a Meningococcal group B vaccine prior to enrolment in this study.\n\nExclusion Criterion for naïve subjects:\n\n• Received any other Meningococcal group B vaccines prior to enrolment in this study.\n\nExclusion Criteria for all subjects:\n\n* Progressive, unstable or uncontrolled clinical conditions.\n* Hypersensitivity, including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study.\n* Abnormal function of the immune system.\n* Received immunoglobulins or any blood products within 180 days prior to informed consent and assent as applicable (according to the subject's age).\n* Received an investigational or non-registered medicinal product within 30 days prior to informed consent and assent as applicable (according to the subject's age).\n* Study personnel as an immediate family or household member.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.\n* Positive results at the urine pregnancy test performed before study vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"15 Years","maximumAge":"24 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)≥1:4","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains 5/99 and NZ98/254. This outcome measure was assessed only for strains 5/99 and NZ98/254.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With hSBA≥1:5","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains H44/76 and M10713. This outcome measure was assessed only for strains H44/76 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"78","spread":null},{"groupId":"OG005","value":"70","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With hSBA Titers≥1:5 in Parent Studies-V72P10 and V72_41","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains H44/76 and M10713","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With hSBA≥1:8","description":"Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"19","spread":null},{"groupId":"OG005","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"71","spread":null},{"groupId":"OG005","value":"63","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With hSBA≥1:16","description":"Bactericidal activity was measured against each of the N. meningitidis group B Indicator strains H44/76,5/99,NZ98/254 and M10713","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"61","spread":null},{"groupId":"OG005","value":"56","spread":null}]}]}]},{"type":"PRIMARY","title":"hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study.","description":"Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76,5/99, NZ98/254 a nd M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":null},{"groupId":"OG001","value":"4.51","spread":null},{"groupId":"OG002","value":"3.05","spread":null},{"groupId":"OG003","value":"1.14","spread":null},{"groupId":"OG004","value":"1.52","spread":null},{"groupId":"OG005","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"606","spread":null},{"groupId":"OG002","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"1.20","spread":null},{"groupId":"OG004","value":"2.30","spread":null},{"groupId":"OG005","value":"1.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"2.56","spread":null},{"groupId":"OG002","value":"1.66","spread":null},{"groupId":"OG003","value":"1.01","spread":null},{"groupId":"OG004","value":"1.50","spread":null},{"groupId":"OG005","value":"1.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"18","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratios (GMRs) of GMTs After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study Versus Day 1.","description":"The GMRs of GMTs at Day 1 versus one month after the last dose of rMenB+OMV NZ vaccination in the parent study were calculated. Bactericidal activity was measured against each of the N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":null},{"groupId":"OG001","value":"0.023","spread":null},{"groupId":"OG002","value":"0.025","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.052","spread":null},{"groupId":"OG002","value":"0.098","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"0.027","spread":null},{"groupId":"OG002","value":"0.073","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":null},{"groupId":"OG001","value":"0.33","spread":null},{"groupId":"OG002","value":"0.81","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Solicited Local and Systemic AEs.","description":"Solicited adverse events are signs and symptoms derived from organized data collection systems, such as Subject Diaries or interview. The percentage and frequencies of subjects reporting solicited local and systemic AEs were tabulated. Threshold for any Erythema, Swelling and Induration: \\>= 25 mm Note:Vaccination 2 was performed only on group B\\_0\\_1 subjects. Threshold for any Erythema, Swelling and Induration: \\>= 25 mm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"226","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"226","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited adverse event is an adverse event that was not solicited using a subject Diary and that was spontaneously communicated by a subject and/or parent(s)/legal guardian(s) who has signed the informed consent. Note : Vaccination 2 was performed only on group B\\_0\\_1 subjects.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any SAEs, AEs Leading to Withdrawal and Medically Attended AEs.","description":"A serious adverse event is any untoward medical occurrence that at any dose results in death or is life threatening or requires prolonged hospitalization, leads to Persistent or significant disability/incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:4 After Booster Dose/First Vaccination of rMenB+OMV NZ.","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains 5/99 and NZ98/254. This outcome measure was assessed only for strains 5/99 and NZ98/254.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"87","spread":null},{"groupId":"OG004","value":"84","spread":null},{"groupId":"OG005","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"62","spread":null},{"groupId":"OG005","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:5 After Booster Dose/First Vaccination of rMenB+OMV NZ.","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains H44/76 and M10713. This outcome measure was assessed only for strains H44/76 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"79","spread":null},{"groupId":"OG005","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:8 After Booster Dose/First Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"67","spread":null},{"groupId":"OG004","value":"74","spread":null},{"groupId":"OG005","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"81","spread":null},{"groupId":"OG004","value":"81","spread":null},{"groupId":"OG005","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"56","spread":null},{"groupId":"OG005","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"79","spread":null},{"groupId":"OG004","value":"89","spread":null},{"groupId":"OG005","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:16 After Booster Dose/First Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99, NZ98/254 \\& M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"49","spread":null},{"groupId":"OG004","value":"65","spread":null},{"groupId":"OG005","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"77","spread":null},{"groupId":"OG004","value":"70","spread":null},{"groupId":"OG005","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"45","spread":null},{"groupId":"OG005","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"66","spread":null},{"groupId":"OG004","value":"84","spread":null},{"groupId":"OG005","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers Prior to Booster/First Dose of Vaccination & Post Booster/First Dose of Vaccination.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76, 5/99,NZ98/254 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":null},{"groupId":"OG001","value":"4.65","spread":null},{"groupId":"OG002","value":"3.10","spread":null},{"groupId":"OG003","value":"1.13","spread":null},{"groupId":"OG004","value":"1.53","spread":null},{"groupId":"OG005","value":"1.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"188","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"1.19","spread":null},{"groupId":"OG004","value":"2.19","spread":null},{"groupId":"OG005","value":"1.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2191","spread":null},{"groupId":"OG001","value":"1951","spread":null},{"groupId":"OG002","value":"2089","spread":null},{"groupId":"OG003","value":"30","spread":null},{"groupId":"OG004","value":"31","spread":null},{"groupId":"OG005","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"2.48","spread":null},{"groupId":"OG002","value":"1.64","spread":null},{"groupId":"OG003","value":"1.00","spread":null},{"groupId":"OG004","value":"1.51","spread":null},{"groupId":"OG005","value":"1.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"3.58","spread":null},{"groupId":"OG004","value":"9.43","spread":null},{"groupId":"OG005","value":"5.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"9.82","spread":null},{"groupId":"OG004","value":"18","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"46","spread":null},{"groupId":"OG005","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMRs) of GMTs After Booster Dose/First rMenB+OMV NZ Vaccination Versus Day 1.","description":"Bactericidal activity was measured against each of the fout N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs one month post-vaccination of a booster dose versus pre-booster dose (follow-on subjects) or first dose of rMenB+OMV NZ versus prefirst dose (naïve subjects) to each N. meningitidis group B indicator strain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"61","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"3.60","spread":null},{"groupId":"OG004","value":"6.43","spread":null},{"groupId":"OG005","value":"4.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.69","spread":null},{"groupId":"OG001","value":"5.16","spread":null},{"groupId":"OG002","value":"4.85","spread":null},{"groupId":"OG003","value":"2.37","spread":null},{"groupId":"OG004","value":"2.58","spread":null},{"groupId":"OG005","value":"2.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Pre Vaccination Compared to One Month Post-booster/First rMenB+OMV NZ Vaccination","description":"The percentage of subjects with 4-fold rise at one month post-vaccination with a booster dose (follow-on subjects) /first dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-first dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer \\< 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but \\<LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"66","spread":null},{"groupId":"OG004","value":"72","spread":null},{"groupId":"OG005","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"79","spread":null},{"groupId":"OG004","value":"74","spread":null},{"groupId":"OG005","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"53","spread":null},{"groupId":"OG005","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"27","spread":null},{"groupId":"OG005","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:4 After Booster Dose/Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains 5/99 and NZ98/254. On day 1, subjects in the Group B\\_0\\_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:\n\nGroup B\\_0\\_1\\_1: blood draws at 3 and 30 days after the second dose. Group B\\_0\\_1\\_2: blood draws at 7 and 30 days after the second dose.\n\nThis outcome measure was assessed only for strains 5/99 and NZ98/254.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"82","spread":null},{"groupId":"OG004","value":"88","spread":null},{"groupId":"OG005","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"32","spread":null},{"groupId":"OG004","value":"60","spread":null},{"groupId":"OG005","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"81","spread":null},{"groupId":"OG005","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"82","spread":null},{"groupId":"OG004","value":"79","spread":null},{"groupId":"OG005","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:5 After Booster Dose/Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains H44/76 and M10713. On day 1, subjects in the Group B\\_0\\_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:\n\nGroup B\\_0\\_1\\_1: blood draws at 3 and 30 days after the second dose. Group B\\_0\\_1\\_2: blood draws at 7 and 30 days after the second dose. This outcome measure was assessed only for strains H44/76 and M10713.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"74","spread":null},{"groupId":"OG004","value":"85","spread":null},{"groupId":"OG005","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"99","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"76","spread":null},{"groupId":"OG004","value":"87","spread":null},{"groupId":"OG005","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"95","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"90","spread":null},{"groupId":"OG004","value":"95","spread":null},{"groupId":"OG005","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:8 After Booster Dose/Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B\\_0\\_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:\n\nGroup B\\_0\\_1\\_1: blood draws at 3 and 30 days after the second dose. Group B\\_0\\_1\\_2: blood draws at 7 and 30 days after the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"70","spread":null},{"groupId":"OG004","value":"80","spread":null},{"groupId":"OG005","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"95","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"97","spread":null},{"groupId":"OG005","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"86","spread":null},{"groupId":"OG005","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"55","spread":null},{"groupId":"OG005","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"68","spread":null},{"groupId":"OG004","value":"70","spread":null},{"groupId":"OG005","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"65","spread":null},{"groupId":"OG004","value":"69","spread":null},{"groupId":"OG005","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"62","spread":null},{"groupId":"OG004","value":"84","spread":null},{"groupId":"OG005","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"93","spread":null},{"groupId":"OG004","value":"94","spread":null},{"groupId":"OG005","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"86","spread":null},{"groupId":"OG004","value":"94","spread":null},{"groupId":"OG005","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:16 After Booster Dose/Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B\\_0\\_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:\n\nGroup B\\_0\\_1\\_1: blood draws at 3 and 30 days after the second dose. Group B\\_0\\_1\\_2: blood draws at 7 and 30 days after the second dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"40","spread":null},{"groupId":"OG004","value":"60","spread":null},{"groupId":"OG005","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"89","spread":null},{"groupId":"OG004","value":"94","spread":null},{"groupId":"OG005","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"90","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"75","spread":null},{"groupId":"OG004","value":"76","spread":null},{"groupId":"OG005","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"98","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"97","spread":null},{"groupId":"OG005","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"40","spread":null},{"groupId":"OG005","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"52","spread":null},{"groupId":"OG005","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"40","spread":null},{"groupId":"OG004","value":"56","spread":null},{"groupId":"OG005","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"50","spread":null},{"groupId":"OG004","value":"76","spread":null},{"groupId":"OG005","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"84","spread":null},{"groupId":"OG004","value":"91","spread":null},{"groupId":"OG005","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"76","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers Prior to Booster/Second Dose of Vaccination & Post Booster/Second Dose of Vaccination.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713. On day 1, subjects in the Group B\\_0\\_1 were to be randomized into 2 different blood draw schedules according to a 1:1 ratio : 2 blood samples at different time points:\n\nGroup B\\_0\\_1\\_1: blood draws at 3 and 30 days after the second dose. Group B\\_0\\_1\\_2: blood draws at 7 and 30 days after the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.41","spread":null},{"groupId":"OG001","value":"4.61","spread":null},{"groupId":"OG002","value":"2.99","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"27","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null},{"groupId":"OG001","value":"4.57","spread":null},{"groupId":"OG002","value":"3.20","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"115","spread":null},{"groupId":"OG003","value":"62","spread":null},{"groupId":"OG004","value":"60","spread":null},{"groupId":"OG005","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"285","spread":null},{"groupId":"OG002","value":"196","spread":null},{"groupId":"OG003","value":"57","spread":null},{"groupId":"OG004","value":"64","spread":null},{"groupId":"OG005","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"33","spread":null},{"groupId":"OG004","value":"30","spread":null},{"groupId":"OG005","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"27","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1969","spread":null},{"groupId":"OG001","value":"1547","spread":null},{"groupId":"OG002","value":"1787","spread":null},{"groupId":"OG003","value":"294","spread":null},{"groupId":"OG004","value":"365","spread":null},{"groupId":"OG005","value":"337","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2147","spread":null},{"groupId":"OG001","value":"1903","spread":null},{"groupId":"OG002","value":"2026","spread":null},{"groupId":"OG003","value":"224","spread":null},{"groupId":"OG004","value":"276","spread":null},{"groupId":"OG005","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"2.40","spread":null},{"groupId":"OG002","value":"1.57","spread":null},{"groupId":"OG003","value":"3.44","spread":null},{"groupId":"OG004","value":"9.79","spread":null},{"groupId":"OG005","value":"5.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":null},{"groupId":"OG001","value":"2.34","spread":null},{"groupId":"OG002","value":"1.62","spread":null},{"groupId":"OG003","value":"2.75","spread":null},{"groupId":"OG004","value":"8.94","spread":null},{"groupId":"OG005","value":"4.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"15","spread":null},{"groupId":"OG005","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"17","spread":null},{"groupId":"OG005","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"50","spread":null},{"groupId":"OG005","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"37","spread":null},{"groupId":"OG005","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"42","spread":null},{"groupId":"OG004","value":"56","spread":null},{"groupId":"OG005","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"116","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"34","spread":null},{"groupId":"OG004","value":"61","spread":null},{"groupId":"OG005","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratios (GMRs) of GMTs After Booster/Second Vaccination Versus Before Booster/Second Vaccination.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713 by calculating the GMRs of GMTs post-vaccination with a booster dose (Group 3B) versus pre-booster dose or second dose (Group B\\_0\\_1) of vaccination versus pre second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"4.21","spread":null},{"groupId":"OG004","value":"2.37","spread":null},{"groupId":"OG005","value":"3.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"6.86","spread":null},{"groupId":"OG004","value":"9.09","spread":null},{"groupId":"OG005","value":"8.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"3.42","spread":null},{"groupId":"OG004","value":"1.76","spread":null},{"groupId":"OG005","value":"2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.87","spread":null},{"groupId":"OG001","value":"5.30","spread":null},{"groupId":"OG002","value":"5.07","spread":null},{"groupId":"OG003","value":"1.36","spread":null},{"groupId":"OG004","value":"1.20","spread":null},{"groupId":"OG005","value":"1.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With at Least Four-fold Increase in hSBA Titers Pre-booster/Second Dose Vaccination- Compared to 3, 7 and 30 Days Post- Booster/Second Vaccination","description":"The percentage of subjects with 4-fold rise at 3, 7, 30 days post-vaccination with a booster dose (follow-on subjects) /second dose (naive subjects) of rMenB+OMV NZ with respect to day 1 (follow-on subjects) / pre-second dose of rMenB+OMV NZ (naïve subjects). Percentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as: • for a pre-vaccination titer \\< 4, a post-vaccination titer of at least 16; • for a pre-vaccination titer ≥ 4 but \\<LLOQ, a post vaccination titer of at least fourfold the LLOQ; • for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"45","spread":null},{"groupId":"OG004","value":"26","spread":null},{"groupId":"OG005","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"55","spread":null},{"groupId":"OG004","value":"63","spread":null},{"groupId":"OG005","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"56","spread":null},{"groupId":"OG004","value":"72","spread":null},{"groupId":"OG005","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"35","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:4 After Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against the N. meningitidis group B indicator strains 5/99 and NZ98/254. Only subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:5 After Second Vaccination of rMenB+OMV NZ","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76 and M10713. Only subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:8 After Second Vaccination of rMenB+OMV NZ.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.\n\nOnly subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA ≥1:16 After Second Vaccination of rMenB+OMV NZ.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.\n\nOnly subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers (GMTs) After Second Vaccination of rMenB+OMV NZ.","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.\n\nOnly subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"1.56","spread":null},{"groupId":"OG002","value":"1.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":null},{"groupId":"OG001","value":"2.18","spread":null},{"groupId":"OG002","value":"1.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"274","spread":null},{"groupId":"OG002","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.58","spread":null},{"groupId":"OG002","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMRs) of GMTs One Month Post Second Vaccination Versus Pre Vaccination at Day 1","description":"Bactericidal activity was measured against each of the four N. meningitidis group B indicator strains H44/76,5/99,NZ98/254 and M10713.\n\nOnly subjects receiving a second vaccination (group B\\_0\\_1) were assessed for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.24","spread":null},{"groupId":"OG001","value":"3.22","spread":null},{"groupId":"OG002","value":"3.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With at Least Four-fold Increase in hSBA Titers at Pre-First Vaccination Compared to One Month Post-Second Vaccination","description":"The percentage of subjects with 4-fold rise at one month post-vaccination with a second dose (naïve subjects) of rMenB+OMV NZ with respect to day 1, to each and any one, two, three or all 4 indicator strains.\n\nPercentage of subjects with four-fold rise in hSBA titers relative to baseline were defined as:\n\n* for a pre-vaccination titer \\< 4, a post-vaccination titer of at least 16;\n* for a pre-vaccination titer ≥ 4 but \\<LLOQ, a post vaccination titer of at least fourfold the LLOQ;\n* for a pre-vaccination titer ≥LLOQ, a post vaccination titer of at least fourfold the pre-vaccination titer.\n\nOnly subjects receiving the second dose of vaccination(group B\\_0\\_1) were considered for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":275},"commonTop":["Injectioon site pain","Injection site erythema","Fatigue","Headache","Injection site induration"]}}}